Revenue
2022
2023
2024
2025
TriSalus Life Sciences, Inc. (TLSI)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Research & development | $15.0M | $17.7M | $29.8M | $21.4M | — |
| Operating income | −$26.9M | −$36.2M | −$54.5M | −$36.4M | −$3.0M |
| EBITDAderived | −$26.3M | −$35.4M | −$53.8M | −$36.0M | — |
| Net income | −$39.2M | −$30.0M | −$59.4M | −$47.2M | $4.8M |
| Basic EPSper diluted share | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
| Diluted EPSper diluted share | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 15, 2026Form 4 | Marshak RichardChief Commercial Officer | SellCommon Stock | 543 | $2.67 | $1.4K | 125.1K |
| May 15, 2026Form 4 | Wahlstrom MatsDirector | BuyCommon Stock | 60.0K | $2.53 | $151.8K | 147.6K |
| May 15, 2026Form 4 | Stansky Michael PDirector | BuyCommon Stock · indirect | 200.0K | $2.50 | $500.0K | 399.7K |
| May 15, 2026Form 4 | Stansky Michael PDirector | BuyCommon Stock | 410.0K | $2.50 | $1.02M | 1.24M |
| May 15, 2026Form 4 | Szela Mary TCEO and President | BuyCommon Stock | 39.7K | $2.59 | $102.8K | 1.07M |